Sugi Predict

Sugi Predict / Compounds / SCHEMBL9852481

SCHEMBL9852481

SCHEMBL9852481

CN(C)c1nc(N)c(C(=O)N=C(N)N)nc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 6/20 1.00
▸ TSHR P16473 5/20 1.00
▸ SLC9A1 P19634 5/20 1.00
▸ FTO Q9C0B1 2/20 1.00
▸ CYP3A4 P08684 1/20 1.00
▸ ALKBH5 Q6P6C2 1/20 1.00
▸ MAPT P10636 1/20 0.97
▸ RAD52 P43351 1/20 0.97
▸ SLC9A5 Q14940 8/20 0.71
▸ CYP2D6 P10635 4/20 0.70
▸ CYP2C19 P33261 3/20 0.70
▸ MEN1 O00255 3/20 0.70
▸ THPO P40225 3/20 0.70
▸ PMP22 Q01453 3/20 0.70
▸ KMT2A Q03164 3/20 0.70
▸ TDP1 Q9NUW8 3/20 0.70
▸ BLM P54132 2/20 0.70
▸ GMNN O75496 2/20 0.70
▸ TP53 P04637 2/20 0.70
▸ NPSR1 Q6W5P4 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29406659 1.00 CYP1A2 (1.00) CYP1A2TSHRSLC9A1FTOCYP3A4
SCHEMBL14513863 0.90 CYP1A2 (0.81) CYP1A2TSHRSLC9A1FTOCYP3A4
SCHEMBL14504168 0.87 CYP1A2 (0.77) CYP1A2TSHRSLC9A1FTOCYP3A4
SCHEMBL14513859 0.86 SLC9A5 (0.77) CYP1A2TSHRSLC9A1FTOCYP3A4
SCHEMBL14504165 0.84 SLC9A5 (0.73) CYP1A2TSHRSLC9A1FTOCYP3A4
SCHEMBL9852519 0.83 CYP1A2 (0.71) CYP1A2TSHRSLC9A1FTOCYP3A4
5-(N-Methyl-N-Isobutyl)Amiloride SCHEMBL29404271 0.83 CYP1A2 (1.00) CYP1A2TSHRSLC9A1FTOCYP3A4
5-(N-Methyl-N-Isobutyl)Amiloride SCHEMBL9852472 0.83 CYP1A2 (1.00) CYP1A2TSHRSLC9A1FTOCYP3A4
SCHEMBL2690754 0.82 PLAU (0.83) CYP1A2TSHRSLC9A1FTOCYP3A4
SCHEMBL14513862 0.82 CYP1A2 (0.69) CYP1A2TSHRSLC9A1FTOCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0451130-A2 Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization CELTRIX PHARMACEUTICALS, INC. (US) 1991-10-09 — — EP claimed
WO-2024112918-A1 RNA DEGRADERS AND USES THEREOF ARRAKIS THERAPEUTICS, INC. (US) 2024-05-30 — — WO disclosed
WO-2023077077-A1 RNA DEGRADERS AND USES THEREOF ARRAKIS THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US disclosed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US disclosed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US disclosed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US disclosed
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2015-11-05 — — US disclosed
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2015-11-05 — — US disclosed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US disclosed
US-20070112013-A1 Method of modulating ion channel functional activity AUSTRALIAN NATIONAL UNIVERSITY (AU) 2007-05-17 — — US disclosed
US-20070112013-A1 Method of modulating ion channel functional activity AUSTRALIAN NATIONAL UNIVERSITY (AU) 2007-05-17 — — US disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed
US-7179803-B1 Method of modulating ion channel functional activity AUSTRALIAN NATIONAL UNIVERSITY (AU) 2007-02-20 — — US disclosed
US-7179803-B1 Method of modulating ion channel functional activity AUSTRALIAN NATIONAL UNIVERSITY (AU) 2007-02-20 — — US disclosed
EP-0451130-A2 Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization CELTRIX PHARMACEUTICALS, INC. (US) 1991-10-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192863-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 CYP1A2 3645/4885TSHR 4658/4885SLC9A1 4403/4885
US-10472332-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 CYP1A2 3645/4885TSHR 4658/4885SLC9A1 4403/4885
US-20070099968-A1 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 CYP1A2 3324/4885TSHR 4665/4885SLC9A1 4386/4885
US-20070112013-A1 Method of modulating ion channel functional activity CACNA1F, CACNA1G, CACNA1B CYP1A2 4653/4885TSHR 4725/4885SLC9A1 631/4885
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS MAVS, ZC3HAV1, EIF2AK2 CYP1A2 3645/4885TSHR 4658/4885SLC9A1 4403/4885
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 CYP1A2 3795/4885TSHR 4699/4885SLC9A1 4316/4885
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 CYP1A2 3795/4885TSHR 4699/4885SLC9A1 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.